Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
LEVOPHED vs DROXIDOPA
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Norepinephrine acts predominantly on alpha-1 adrenergic receptors to cause vasoconstriction and increase blood pressure. It also has beta-1 adrenergic receptor agonist activity, resulting in positive inotropic effects on the heart.
Droxidopa is a synthetic precursor of norepinephrine that increases norepinephrine levels in the peripheral nervous system, thereby improving sympathetic tone and blood pressure regulation.
Treatment of hypotension in acute hypotensive states (e.g., septic shock, myocardial infarction, blood loss),Adjunct in the treatment of cardiac arrest (off-label)
Treatment of neurogenic orthostatic hypotension (n OH) in adult patients with primary autonomic failure (e.g., Parkinson's disease, multiple system atrophy, pure autonomic failure) or secondary autonomic failure (e.g., diabetes, amyloidosis)
Initial dose: 8-12 mcg/min intravenously, titrate to desired blood pressure; typical maintenance: 2-4 mcg/min IV continuous infusion.
100-200 mg orally three times daily, with a maximum of 600 mg three times daily if needed.
The terminal elimination half-life is approximately 2 minutes. The clinical effect is short-lived due to rapid reuptake and metabolism; continuous intravenous infusion is required for sustained effect.
2–3 hours; terminal half-life approximately 2.5 hours, requiring 3–4 times daily dosing to maintain plasma levels.
Primarily metabolized in the liver by catechol-O-methyltransferase (COMT) and monoamine oxidase (MAO).
Metabolized by aromatic L-amino acid decarboxylase (AAAD) to norepinephrine, and also undergoes catechol-O-methyltransferase (COMT) metabolism.
Norepinephrine is primarily metabolized in the liver and other tissues by catechol-O-methyltransferase (COMT) and monoamine oxidase (MAO). Less than 5% is excreted unchanged in urine. Metabolites are excreted renally (approximately 80-95% as normetanephrine, vanillylmandelic acid, and other conjugates).
Renal: ~75% as unchanged drug and metabolites (including 3-O-methyldroxidopa and other conjugates); biliary/fecal: minimal (<5%).
Approximately 25-30% bound to albumin and other plasma proteins.
~75% (primarily to albumin).
Approximately 0.7-1.0 L/kg. This indicates moderate distribution into tissues and plasma, consistent with a hydrophilic catecholamine.
1–1.5 L/kg; indicates extensive tissue distribution.
Bioavailability is 100% via intravenous administration. Oral bioavailability is negligible due to extensive first-pass metabolism; not administered orally. Intramuscular or subcutaneous administration results in erratic absorption and significant vasoconstriction leading to poor bioavailability; thus, intravenous infusion is the only reliable route.
Oral: ~40% (range 30–50%) due to first-pass metabolism.
No specific dose adjustment required for renal impairment; titrate to clinical response.
For GFR 15-29 m L/min: reduce dose to 100 mg twice daily. For GFR <15 m L/min or dialysis: 100 mg once daily or 100 mg every other day.
No specific dose adjustment required for hepatic impairment; titrate to clinical response.
No specific Child-Pugh based adjustments; contraindicated in severe hepatic impairment (Child-Pugh C). Use with caution in moderate impairment (Child-Pugh B) at reduced doses.
Initial: 0.05-0.1 mcg/kg/min IV continuous infusion, titrate to effect; maximum dose not established.
Safety and efficacy not established in pediatric patients; no standard weight-based dosing available.
Start at lower end of dosing range (2-4 mcg/min IV) due to increased sensitivity and comorbidities; titrate cautiously.
Start at lower end of dosing range (100 mg twice daily) due to increased risk of orthostatic hypotension and renal function decline; monitor blood pressure and adjust gradually.
No FDA boxed warning exists for LEVOPHED.
No FDA black box warning.
Risk of extravasation leading to tissue necrosis; ensure proper IV access and avoid infiltration,Monitor blood pressure, heart rate, and cardiac output continuously,May cause ischemia to limbs, kidneys, and splanchnic organs due to vasoconstriction,Use with caution in patients with hypertension, hyperthyroidism, or myocardial ischemia,Abrupt discontinuation may cause rebound hypotension
May cause supine hypertension; monitor blood pressure and manage by reducing dose or discontinuing if severe.,Risk of exacerbation of cardiovascular disease (e.g., arrhythmias, heart failure).,May cause hyperthermia and confusion in patients with Parkinson's disease (resembles neuroleptic malignant syndrome).,Potential for increased risk of hallucinations or other psychiatric effects.,Use with caution in patients with pre-existing cerebrovascular or cardiovascular disease.
Hypersensitivity to norepinephrine or any component of the formulation,Hypovolemia (should be corrected before or during therapy),Use with cyclopropane or halothane anesthesia (increases risk of ventricular arrhythmias),Severe peripheral vascular disease with risk of gangrene
Hypersensitivity to droxidopa or any component of the formulation.,Use in patients with significant cardiovascular disease (e.g., unstable angina, recent myocardial infarction, or severe ventricular arrhythmias) is contraindicated.,Concomitant use with non-selective MAO inhibitors (e.g., phenelzine, tranylcypromine) due to risk of hypertensive crisis.
No clinically significant food interactions. Monitor for hyperglycemia in diabetic patients due to alpha-adrenergic effects.
Avoid alcohol as it may exacerbate hypotension. No specific food interactions known; take with or without food. High-tyramine foods (e.g., aged cheeses, cured meats) are not contraindicated but monitor blood pressure if consuming large amounts.
Norepinephrine is a catecholamine that does not cross the placenta extensively. Animal studies have not shown teratogenicity, but human data are limited. Inadequate uteroplacental blood flow due to maternal vasoconstriction may cause fetal hypoxia and bradycardia. Use only if clearly needed, and monitor fetal heart rate. FDA Pregnancy Category C.
Pregnancy Category C. In animal studies, droxidopa caused decreased fetal weights and increased skeletal variations at doses 2.6 times the maximum recommended human dose. There are no adequate and well-controlled studies in pregnant women. Fetal risk cannot be ruled out; use only if potential benefit justifies potential risk to the fetus.
Norepinephrine is not expected to be excreted into breast milk in clinically significant amounts due to its short half-life and rapid metabolism. M/P ratio not established. Use with caution in breastfeeding women, as effects on the infant are unknown.
No data available on presence in human milk, effects on breastfed infant, or milk production. Caution advised. M/P ratio unknown.
Pregnancy may alter the pharmacokinetics of norepinephrine, but specific dose adjustments are not established. Monitor maternal blood pressure closely and titrate to the lowest effective dose to maintain adequate uteroplacental perfusion. Starting dose is typically 0.5-1 mcg/min, titrated to effect.
No specific pharmacokinetic data in pregnancy; dose adjustment not recommended due to lack of evidence. Use lowest effective dose. Monitor for hypotension and supine hypertension.
LEVOPHED (norepinephrine) is a first-line vasopressor for septic shock. Administer via central line to avoid extravasation injury; if extravasation occurs, treat with phentolamine 5-10 mg in 10 m L saline infiltrated locally. Titrate to mean arterial pressure (MAP) ≥ 65 mm Hg. Taper gradually to avoid rebound hypotension.
Droxidopa is a prodrug of norepinephrine used for symptomatic neurogenic orthostatic hypotension (NOH). Monitor supine hypertension closely; advise patients to avoid dose lying down. Onset of action is within 1 hour, peak effect at 3-4 hours, duration about 6-8 hours. Titrate based on symptoms and supine blood pressure. Do not administer within 5 hours of bedtime to reduce risk of nocturnal supine hypertension. Can be used with fludrocortisone or midodrine, but additive hypertension risk.
This medication is used to treat dangerously low blood pressure.,It will be given intravenously (IV) in a hospital setting by healthcare professionals.,You may feel anxiety, headache, or heart palpitations as the medication works.,Report any pain, redness, or swelling at the IV site immediately.,Do not stop the medication abruptly; it must be tapered under medical supervision.
Take droxidopa exactly as prescribed, usually three times daily: on waking, mid-day, and late afternoon—never within 5 hours of bedtime.,Do not lie down after taking a dose; remain upright (sitting or standing) to prevent severe high blood pressure while lying down.,Rise slowly from sitting or lying positions to reduce falls; symptoms of low blood pressure include dizziness, lightheadedness, and fainting.,Avoid alcohol, which can worsen low blood pressure and increase side effects like dizziness.,Report symptoms of high blood pressure when lying down: severe headache, blurred vision, chest pain, difficulty breathing.,Store at room temperature; keep away from moisture and heat.
No interactions on record
"Betahistine, a histamine analog, may reduce the therapeutic efficacy of droxidopa, a prodrug converted to norepinephrine for the treatment of symptomatic neurogenic orthostatic hypotension. The proposed physiological effect is that betahistine's H1- and H3-receptor agonistic and antagonistic activities could counteract the pressor response of norepinephrine, leading to suboptimal blood pressure elevation. Clinically, this may result in inadequate control of orthostatic hypotension symptoms, such as dizziness and syncope, when both agents are used concomitantly."
"Droxidopa, a synthetic amino acid converted to norepinephrine, directly elevates blood pressure, opposing the antihypertensive effects of mirtazapine. Mirtazapine, an atypical antidepressant with alpha-2 antagonism, may further enhance norepinephrine release, potentially synergizing with droxidopa's pressor effect. This interaction can lead to reduced efficacy of mirtazapine in managing hypertension and may increase risk of hypertensive crisis."
"Droxidopa, a prodrug of norepinephrine, is used to increase blood pressure in patients with neurogenic orthostatic hypotension. Tianeptine, an atypical antidepressant with opioid receptor activity, can cause bradycardia and hypotension. The combination may lead to an antagonistic effect where tianeptine's hypotensive properties reduce the pressor efficacy of droxidopa, potentially resulting in inadequate blood pressure control and recurrence of orthostatic hypotension symptoms."
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about LEVOPHED vs DROXIDOPA, answered by our medical review team.
LEVOPHED is a Vasopressor that works by Norepinephrine acts predominantly on alpha-1 adrenergic receptors to cause vasoconstriction and increase blood pressure. It also has beta-1 adrenergic receptor agonist activity, resulting in positive inotropic effects on the heart.. DROXIDOPA is a Vasopressor that works by Droxidopa is a synthetic precursor of norepinephrine that increases norepinephrine levels in the peripheral nervous system, thereby improving sympathetic tone and blood pressure regulation.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between LEVOPHED and DROXIDOPA depend on the specific clinical indication. These are both Vasopressor agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of LEVOPHED is: Initial dose: 8-12 mcg/min intravenously, titrate to desired blood pressure; typical maintenance: 2-4 mcg/min IV continuous infusion.. The standard adult dose of DROXIDOPA is: 100-200 mg orally three times daily, with a maximum of 600 mg three times daily if needed.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between LEVOPHED and DROXIDOPA in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. LEVOPHED is classified as Category C. Norepinephrine is a catecholamine that does not cross the placenta extensively. Animal studies have not shown teratogenicity, but human data are limited. Inadequate uteroplacental . DROXIDOPA is classified as Category C. Pregnancy Category C. In animal studies, droxidopa caused decreased fetal weights and increased skeletal variations at doses 2.6 times the maximum recommended human dose. There are. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.